Ann Surg Treat Res.  2017 Oct;93(4):186-194. 10.4174/astr.2017.93.4.186.

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer

• Kim HS
• Jang JY
• Han Y
• Lee KB
• Joo I
• Lee DH
• Kim JR
• Kim H
• Kwon W
• Kim SW

• KMID: 2392368
• DOI: http://doi.org/10.4174/astr.2017.93.4.186

Abstract

PURPOSE
Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors.
METHODS
Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively.
RESULTS
The mean age was 61.7 years and the male-to-female ratio was 1.8:1. Twenty-six, 3, and 11 patients received gemcitabine-based chemotherapy, 5-fluorouracil, and FOLFIRINOX, respectively. The 2-year survival rate (2YSR) was 36.6% and the median overall survival (OS) was 20 months. Of the 40 patients, 34 patients underwent resection and the 2YSR was 41.2% while the 2YSR of patients who did not undergo resection was 16.7% (P = 0.011). The 2YSR was significantly higher in patients who had partial response compared to stable disease (60.6% vs. 24.3%, P = 0.038), in patients who did than did not show a CA 19-9 response after neoadjuvant treatment (40.5% vs. 0%, P = 0.039) and in patients who did than did not receive radiotherapy (50.8% vs. 25.3%, P = 0.036). Five patients had local recurrence and 17 patients had systemic recurrence with a median disease specific survival of 15 months.
CONCLUSION
Neoadjuvant treatment followed by resection is effective for BRPC. Pancreatectomy and neoadjuvant treatment response may affect survival. Effective systemic therapy is needed to improve long-term survival since systemic metastasis accounts for a high proportion of recurrence.

Keyword

Pancreatic neoplasms; Neoadjuvant therapy; Surgery; Prognosis

MeSH Terms

Drug Therapy
Fluorouracil
Humans
Neoadjuvant Therapy*
Neoplasm Metastasis
Pancreatectomy
Pancreatic Neoplasms*
Prognosis
Prospective Studies
Radiotherapy
Recurrence
Retrospective Studies
Survival Rate
Fluorouracil

Figure

• 

  Fig. 1 Overall survival curve after neoadjuvant treatment followed by operation. 2YSR, 2-year survival rate.

• 

  Fig. 2 Survival curves according to the factors. (A) Survival curves according to the chemotherapy regimen, radiotherapy; (B) survival curves according to the neoadjuvant treatment response, RECIST criteria or CA 19-9 change; (C) survival curves according to the pancreatectomy. 2YSR, 2-year survival rate; 5-FU, 5-fluorouracil; RT, radiotherapy; RECIST, Response Evaluation Criteria In Solid Tumors; PR, partial response; SD, stable disease.

• 

  Fig. 3 Pancreatectomy subgroup survival curves according to the factors. (A) Survival curves according to the chemotherapy regimen, radiotherapy; (B) survival curve according to the resection status, lymph node metastasis. 2YSR, 2-year survival rate; 5-FU, 5-fluorouracil; RT, radiotherapy.

• 

  Fig. 4 Disease-free survival curve after neoadjuvant treatment followed by operation.

Reference

1. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016; 48:436–450.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29.

3. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206:833–846.

4. National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, version 2. 2014 [Internet]. Fort Wathington (PA): National Comprehensive Cancer Network;c2017. cited 2014 Jul 16. Available from: http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.

5. Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas. 2009; 38:282–288.

6. Festa V, Andriulli A, Valvano MR, Uomo G, Perri F, Andriulli N, et al. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP. 2013; 14:618–625.

7. Kang HJ, Lee JM, Joo I, Hur BY, Jeon JH, Jang JY, et al. Assessment of malignant potential in intraductal papillary mucinous neoplasms of the pancreas: comparison between multidetector CT and MR imaging with MR cholangiopancreatography. Radiology. 2016; 279:128–139.

8. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13:176–181.

9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228–247.

10. Kang MJ, Jang JY, Lee SE, Lim CS, Lee KU, Kim SW. Comparison of the long-term outcomes of uncinate process cancer and non-uncinate process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence. Langenbecks Arch Surg. 2010; 395:697–706.

11. Eom BW, Jang JY, Lee SE, Han HS, Yoon YS, Kim SW. Clinical outcomes compared between laparoscopic and open distal pancreatectomy. Surg Endosc. 2008; 22:1334–1338.

12. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13:1035–1046.

13. Magnin V, Moutardier V, Giovannini MH, Lelong B, Giovannini M, Viret F, et al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003; 55:1300–1304.

14. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006; 13:1201–1208.

15. Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park DH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012; 152:851–862.

16. Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013; 258:1040–1050.

17. Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, et al. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016; 159:893–900.

18. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350:1200–1210.

19. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297:267–277.

20. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817–1825.

21. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18:543–548.

22. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014; 19:266–274.

23. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011; 29:4105–4112.

24. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985; 3:373–378.